Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Appropriateness of B12 Administration in a Real-World Population

William K Silverstein, MD, Yulia Lin, MD FRCPC, Christoffer Dharma, MSc, Ruth Croxford, MSc, Matthew Cheung, MD MS, FRCP

Blood (2018) 132 (Supplement 1): 2227.

https://doi.org/10.1182/blood-2018-99-110264

Published: 2018

Journal Articles

High Healthcare Utilization and Costs in Patients with Higher-Risk MDS/Low Blast Count AML Treated with Azacitidine in Ontario, Canada

Lee Mozessohn, MD, Matthew Cheung, MD MS, FRCP, Nicole Mittmann, PhD, Craig C. Earle, MD, Ning Liu, Rena Buckstein, MD FRCPC

Blood (2018) 132 (Supplement 1): 834.

https://doi.org/10.1182/blood-2018-99-110223

Published: 2018

Journal Articles

Cost-Effectiveness and Cost-Utility Analysis of ABVD Versus Beacopp in the Treatment of Advanced-Stage Hodgkin Lymphoma

Abi Vijenthira, MD, Kelvin Chan, MD PhD, Matthew Cheung, MD MS, FRCP, Anca Prica, MD

Blood (2018) 132 (Supplement 1): 2248.

https://doi.org/10.1182/blood-2018-99-113103

Published: 2018

Journal Articles

Examining Convergent Construct Validity and Inter-Rater Reliability Between ESMO-MCBS and ASCO-VF When Evaluating Hematologic Malignancies

Matthew Cheung, MD MS, FRCP, Ihsan Albakri, Robert Mason, Ronak Saluja, Sierra Cheng, Vanessa Arciero, Louis Everest, Kelvin Chan, MD PhD

Blood (2018) 132 (Supplement 1): 4800.

https://doi.org/10.1182/blood-2018-99-119631

Published: 2018

Journal Articles

Diagnosis to Treatment Interval in DLBCL Is Predictive of Overall Survival in a Large, Population-Based Registry

Danielle N. Blunt, BMBS, Liam Smyth, MD FRCPath, Evgenia Gatov, Chenthila Nagamuthu, MPH, Rena Buckstein, MD FRCPC, Ruth Croxford, MSc, Matthew Cheung, MD MS, FRCP

Blood (2018) 132 (Supplement 1): 1700.

https://doi.org/10.1182/blood-2018-99-120313

Published: 2018

Journal Articles

Improved Survival in Overweight and Obese Patients with Non-Hodgkin's Lymphoma Treated with Rituximab Containing Chemotherapy for Curative Intent

James K R Stevenson, MD MSc, Lucy Qiao, MS, MPH, Kelvin Chan, MD PhD, Jaclyn Beca, MSc, Wanrundee Isaranuwatchai, PhD, Helen Guo, BS, Deborah Schwarz, PhD, Jessica Arias, BA, MACP, Scott Gavura, BSPharm, MBA, C. Tom Kouroukis, MDMSc,FRCPC, Matthew Cheung, MD MS, FRCP

Blood (2017) 130 (Supplement 1): 1557.

https://doi.org/10.1182/blood.V130.Suppl_1.1557.1557

Published: 2017

Journal Articles

Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Anca Prica, MD FRCP(C), Annette E Hay, Michael Crump, MD, Nicole Mittman, Lois E. Shepherd, Ralph Meyer, MDFRCPC, Kevin Imrie, MD, Nancy A. Risebrough, Marina S Djurfeldt, MSc, Bingshu E. Chen, Matthew Cheung, MD MS, FRCP

Blood (2017) 130 (Supplement 1): 4673.

https://doi.org/10.1182/blood.V130.Suppl_1.4673.4673

Published: 2017

Journal Articles

Prolonged Molecular and Clinical Remissions in Follicular Lymphoma Patients Treated with HDT/ASCT and Combination Immunotherapy with Rituximab and Interferon α

Liam Smyth, MD FRCPath, Rena Buckstein, MD FRCPC, Pennell Nancy, BSc, Rashmi Weerasinghe, Matthew Cheung, MD MS, FRCP, Eugenia Piliotis, MD FRCP, MD, Kevin Imrie, MD, David Spaner, MD PhD, Marciano D. Reis, MD, Lisa Chodirker, MD, Zeina Ghorab, Violet ruth,nancy Milliken, Angela Boudreau, RN, BScN, MN, CON(C), Neil Berinstein, MD

Blood (2017) 130 (Supplement 1): 4069.

https://doi.org/10.1182/blood.V130.Suppl_1.4069.4069

Published: 2017

Journal Articles

Days Spent at Home in the Last 6 Months of Life. a Potential Patient-Determined Quality Indicator for Patients with Hematologic Malignancies at the End of Life

Matthew Cheung, MD MS, FRCP, Sarah Andersen, MD, Craig C. Earle, MDMSc, Ruth Croxford, Simron Singh, MD MS, FRCPC

Blood (2017) 130 (Supplement 1): 281.

https://doi.org/10.1182/blood.V130.Suppl_1.281.281

Published: 2017

Journal Articles

Combined Modality Therapy Versus Chemotherapy Alone As an Induction Regimen for Primary CNS Lymphoma: A Cost-Effectiveness Analysis

Anca Prica, MD, Kelvin KW Chan, MD, MSc, FRCPC, Matthew Cheung, MD, MS, FRCP

Blood (2012) 120 (21): 969.

https://doi.org/10.1182/blood.V120.21.969.969

Published: 2012

Journal Articles

First Evidence for High Incidence of Complete and Sustained Molecular Remissions and Maintenance of Immune Responses in Patients Receiving Consolidation with Y90 Ibritumomab Tiuxetan ( 90 Y-RIT) Post R-CHOP for Newly Diagnosed Advanced Stage High and Intermediate Risk Follicular Lymphoma

Nancy M Pennell, B Sc, Matthew Cheung, MD, MS, FRCP, Lisa K Hicks, MD, MSc, FRCPC, Eugenia Piliotis, MD, FRCPC, Kevin R Imrie, MD, Rena Buckstein, MD, FRCPC, Cindy Davidson, RN, Mary-Anne Cussen, RN, BScN, CCRP, Zeina Ghorab, MD, Alden Chesney, MD, FRCPC, Neil L Berinstein, MD, FRCPC

Blood (2011) 118 (21): 2701.

https://doi.org/10.1182/blood.V118.21.2701.2701

Published: 2011

NARROW

Appropriateness of B12 Administration in a Real-World Population

High Healthcare Utilization and Costs in Patients with Higher-Risk MDS/Low Blast Count AML Treated with Azacitidine in Ontario, Canada

Cost-Effectiveness and Cost-Utility Analysis of ABVD Versus Beacopp in the Treatment of Advanced-Stage Hodgkin Lymphoma

Examining Convergent Construct Validity and Inter-Rater Reliability Between ESMO-MCBS and ASCO-VF When Evaluating Hematologic Malignancies

Diagnosis to Treatment Interval in DLBCL Is Predictive of Overall Survival in a Large, Population-Based Registry

Improved Survival in Overweight and Obese Patients with Non-Hodgkin's Lymphoma Treated with Rituximab Containing Chemotherapy for Curative Intent

Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Prolonged Molecular and Clinical Remissions in Follicular Lymphoma Patients Treated with HDT/ASCT and Combination Immunotherapy with Rituximab and Interferon α

Days Spent at Home in the Last 6 Months of Life. a Potential Patient-Determined Quality Indicator for Patients with Hematologic Malignancies at the End of Life

Combined Modality Therapy Versus Chemotherapy Alone As an Induction Regimen for Primary CNS Lymphoma: A Cost-Effectiveness Analysis

First Evidence for High Incidence of Complete and Sustained Molecular Remissions and Maintenance of Immune Responses in Patients Receiving Consolidation with Y90 Ibritumomab Tiuxetan ( 90 Y-RIT) Post R-CHOP for Newly Diagnosed Advanced Stage High and Intermediate Risk Follicular Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only